Elpis Biopharmaceuticals Debuts with Series A Funding and Establishment of Scientific Advisory Board
Elpis Biopharmaceuticals Debuts with Series A Funding and Establishment of Scientific Advisory Board
10/29/20, 11:10 AM
Location
Round Type
series a
Elpis Biopharmaceuticals today announced the closing of a $30 million Series A financing to propel solid tumor and hematological disease therapeutics through pre-clinical studies, which brings the company to a total of $40 million raised including seed funding. The investment is part of a new strategic partnership with a global pharmaceutical company.
Company Info
Location
lexington, south carolina, united states
Additional Info
Elpis Biopharmaceuticals is developing multifunctional immunotherapies, including dual-targeted armored CAR-T cells and bispecific biologics, aimed at activating the immune system to overcome tumor resistance. Through its proprietary antibody discovery and protein engineering platforms, Elpis is advancing a rich pipeline to treat solid tumors and hematological malignancies with the goal of improving outcomes for patients with difficult-to-treat and resistant cancers. Elpis is headquartered in Lexington, MA, with research labs in the U.S. and China.